Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Free Access

The Risk of Parkinson Disease Associated with Urate in a Community-Based Cohort of Older Adults

Jain S.a, c · Ton T.G.e · Boudreau R.M.b · Yang M.b · Thacker E.L.f · Studenski S.d · Longstreth, Jr. W.T.e · Strotmeyer E.S.b · Newman A.B.b, d

Author affiliations

aPittsburgh Institute for Neurodegenerative Diseases, bDepartment of Epidemiology, University of Pittsburgh Graduate School of Public Health, and cDepartment of Neurology, dUniversity of Pittsburgh School of Medicine, Pittsburgh, Pa., and Departments of eNeurology and fEpidemiology, University of Washington, Seattle, Wash., USA

Corresponding Author

Samay Jain, MD, MS

Department of Neurology, University of Pittsburgh Medical Center

3471 Fifth Ave., Suite 811

Pittsburgh, PA 15213-3232 (USA)

Tel. +1 412 692 4916, E-Mail jains@upmc.edu

Related Articles for ""

Neuroepidemiology 2011;36:223–229

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background/Aims: Studies suggest an inverse association between urate concentration and the risk of Parkinson disease (PD). We investigated this in the Cardiovascular Health Study in an elderly community-based cohort of adults. Methods: The association of baseline urate (µmol/l) and incident PD over 14 years was assessed with locally weighted scatterplot smoothing (LOESS) regression from which categories of low (<300 µmol/l), middle (300–500 µmol/l), and high (>500 µmol/l) urate ranges were derived. Multivariate logistic regression models assessed the risk of PD for each urate range. Linear and quadratic terms were tested when modeling the association between urate and the risk of PD. Results: Women had significantly lower urate concentrations than did men [316.8 µmol/l (SD 88.0) vs. 367.4 µmol/l (SD 87.7), p < 0.0001] and in women no associations between urate and PD risk were observed. In men, LOESS curves suggested a U-shaped or threshold effect between urate and PD risk. With the middle range as reference, the risk of developing PD was significantly increased for urate <300 µmol/l (OR 1.69, 95% CI 1.03–2.78) but not for urate >500 µmol/l (OR 1.55, 95% CI 0.72–3.32) in men. A negative linear term was significant for urate <500 µmol/l, and across the entire range a convex quadratic term was significant. Conclusions: Results suggest a more complex relationship than previously reported between urate levels and the risk of PD in men. Low urate concentrations were associated with a higher PD risk and high urate concentrations were not associated with a further decrease in PD risk.

© 2011 S. Karger AG, Basel


  1. Schlesinger I, Schlesinger N: Uric acid in Parkinson’s disease. Mov Disord 2008;23:1653–1657.
  2. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM: Serum uric acid levels and the risk of Parkinson disease. Annals Neurol 2005;58:797–800.
  3. Davis JW, Grandinetti A, Waslien CI, Ross GW, White LR, Morens DM: Observations on serum uric acid levels and the risk of idiopathic Parkinson’s disease. Am J Epidemiol 1996;144:480–484.
  4. Weisskopf MG, O’Reilly E, Chen H, Schwarzschild MA, Ascherio A: Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 2007;166:561–567.
  5. Annanmaki T, Muuronen A, Murros K: Low plasma uric acid level in Parkinson’s disease. Mov Disord 2007;22:1133–1137.
  6. Chen HM, Mosley TH, Alonso A, Huang X: Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) Study. American J Epidemiol 2009;169:1064–1069.
  7. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G: The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008;392:1–7.
  8. Strazzullo P, Puig JG: Uric acid and oxidative stress: relative impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 2007;17:409–414.
  9. Fried LP, Borhani NO, Enright P, et al: The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263–276.
  10. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO: Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3:358–366.
  11. Ton TG, Jain S, Boudreau B, Thacker EL, Strotmeyer ES, Newman AB, Longstreth WT, Checkoway H: Post hoc Parkinson’s: Identifying an uncommon disease in the Cardiovascular Health Study. Neuroepidemiology 2010;35:241–249.
  12. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP: Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995;41:264–270.
  13. Chonchol M, Shlipak MG, Katz R, et al: Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239–247.
  14. Shlipak MG, Fried LF, Cushman M, et al: Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005;293:1737–1745.
  15. Kumar A, Prineas RJ, Arnold AM, et al: Prevalence, prognosis, and implications of isolated minor nonspecific ST-segment and T-wave abnormalities in older adults: Cardiovascular Health Study. Circulation 2008;118:2790–2796.
  16. O’Reilly EJ, Gao X, Weisskopf MG, et al: Plasma urate and Parkinson’s disease in women. Am J Epidemiol 2010;172:666–670.
  17. Nilsen J, Brinton RD: Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Disord 2004;3:297–313.
  18. Tell GS, Rutan GH, Kronmal RA, et al: Correlates of blood pressure in community-dwelling older adults: the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. Hypertension 1994;23:59–67.
  19. Ekundayo OJ, Dell’Italia LJ, Sanders PW, et al: Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol 2010;142:279–287.
  20. Edwards NL: The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol 2009;21:132–137.
  21. Beach TG, Adler CH, Sue LI, et al: Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119:689–702.
  22. Orimo S, Uchihara T, Nakamura A, et al: Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain 2008;131:642–650.
  23. Miyake Y, Tanaka K, Fukushima W, et al: Case-control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 2010;293:82–86.
  24. Shah A, Keenan RT: Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? Curr Rheumatol Rep 2010;12:118–124.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: December 13, 2010
Accepted: March 17, 2011
Published online: June 16, 2011
Issue release date: July 2011

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 2

ISSN: 0251-5350 (Print)
eISSN: 1423-0208 (Online)

For additional information: https://www.karger.com/NED

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.